Countdown to 2030: Stronger alignment for country impact
Ahead of the 77th World Health Assembly, the 13 signatory agencies of the Global Action Plan for Healthy Lives and Well-being for All (SDG3 GAP) have released their fifth progress report, Aligning for Country Impact. Past the crucial SDG midpoint, with only 15% of the 50+ health-related SDGs on track to reach their 2030 targets, the SDG3 GAP’s goal remains the same: multilateral collaboration evolves in response to a rapidly changing world and, crucially, in alignment with country priorities and needs.
In 2024, the SDG3 GAP approach has been used in 69 countries. Country case studies in the report, illustrate how the commitment to stronger collaboration is being translated into reality at country level. This fifth progress report amplifies countries’ voices and notes their calls for greater alignment among development partners around national plans, most recently through the second round of the SDG3 GAP monitoring framework government feedback. The analysis of this year’s feedback presents successes and challenges in both coordination and collaboration and proposes corrective measures for the way forward. Using this approach, countries have been able to suggest specific improvements for collaboration and coordination at all levels. Moving forward, development partners can consider these suggestions and best practices, to enable both strong country leadership, and strong alignment with national health-sector strategies and national planning and coordination mechanisms.
The report reflects on the lessons learned so far and actions taken to implement recommendations from last year’s report. This includes revisiting the accelerators (programmatic areas crucial to accelerating progress on the health-related SDGs), acknowledging that stronger leadership and enhanced cross-accelerator collaborations drive increased alignment at the country level. Successes under accelerator themes over the past year include, the work of the Primary Health Care accelerator, which has focused support to 20 priority countries to develop and deliver a comprehensive package of essential health services. The Sustainable Financing for Health accelerator, which has provided a platform for partners to provide inputs into the Future of Global Health Initiatives Process, is providing a range of pooled or co-financed operations in countries and has identified some key issues and lessons learned from their joint financing of health-systems strengthening in low- and middle-income countries.
In recognizing the importance of leveraging strengths and partnerships, the agencies support alignment with emerging agendas such as the conclusion of the Future of Global Health Initiatives Process, which captures consensus around five key shifts for the long term evolution of global health initiatives, known as the Lusaka Agenda, and new strategies such as Gavi’s 6.0 Health Systems Strategy, World Bank’s Evolution Roadmap and WHO’s 14th Global Program of Work. Additionally, they continue to improve alliances with initiatives including UHC2030, to support countries in meeting their universal health care commitments.
“Progress towards meeting the health-related targets of the 2030 SDGs is only about one-third of what is needed,” said WHO Director-General Tedros Adhanom Ghebreyesus, Chair of the SDG3 GAP Principals Group. “The SDG3 GAP is founded on the idea that stronger collaboration between multilateral agencies can help us get back on track. This report takes stock of achievements and lessons learned during these years and provides directions for how SDG3 GAP should evolve going forward in our joint efforts for better health for all.”
Incentives for collaboration, including the cost of collaboration, still hold back fulfilling the immense potential for stronger collaboration and alignment both within the SDG3 GAP and across the multilateral system. Constrained financial, technical and operational resources mean that development partners’ accountability mechanisms on collaboration across the broader health ecosystem are limited.
The findings of an Independent Evaluation of the SDG3 GAP are expected in September 2024. The evaluation results could prompt a rethinking of approaches taken thus far, both inside the scope of SDG3 GAP, and outside of its structures. This progress report contributes to the basis for further discussions among the signatory agencies and relevant stakeholders, on how to further improve the alignment and collaboration across the global health ecosystem to achieve progress towards the health-related SDGs.
Quotes from SDG3 GAP Principals
Dr Sania Nishtar, CEO, Gavi, the Vaccine Alliance:
“Gavi strives to make a sustainable impact on global health by ensuring our actions are in harmony with countries’ efforts to improve public health and well-being. Our role in the Sustainable Financing for Health Accelerator underscores our dedication to helping countries rapidly improve the generation, allocation, and use of funds for health. By working together, we can build robust health systems that will withstand current and future global health challenges.”
Juan Pablo Uribe, Global Director for Health, Nutrition and Population, World Bank and Director, Global Financing Facility for Women, Children and Adolescents:
“Ensuring better health for women, children and adolescents is the foundation of prosperous societies and resilient growth. With a clear call from countries for better alignment behind their health plans, the Global Financing Facility will continue to focus on supporting countries for stronger coordination with partners and aligned financing to accelerate health progress for women, children and adolescents, particularly in the hardest to reach communities.”
Gilbert F. Houngbo, Director-General, International Labour Organization:
“The ILO is committed to promoting a social justice approach to investments in health and care as a contribution to achieving the SDG 3 targets. This includes investments in social protection, occupational safety and health, and decent work for health and care workers.”
Peter Sands, Executive Director, The Global Fund:
“The world is beset by interlocking and intersecting crises. These crises, and those looming on the horizon, are exposing the fragility of advances in human health and development. The Global Fund’s partnership model is the foundation for successful implementation of the SDGs. Restoring advancement toward the SDGs and future-proofing progress requires agile, collaborative, well-resourced and resilient systems for health that leave no one behind when crises inevitably strike.”
Winnie Byanyima, Executive Director, UNAIDS:
“Too many countries are struggling to meet the health needs of their people. The good news is that we know what needs to be done. World leaders need to urgently boost public financing for health, and fix the global debt crisis that is draining vital resources needed to save lives. Leaders need to support communities to lead, so that health systems can meet people’s needs. And leaders need protect everyone’s human rights, so that all people can access all services without fear or stigma. With courage, commitment, and collaboration, health for all can be secured.”
Achim Steiner, Administrator, United Nations Development Programme:
“The continued, slow recovery from the COVID-19 pandemic and the crushing weight of debt servicing in many developing countries is curtailing critical investments in healthcare and health systems. At the same time, conflicts, crises, and a changing climate are inflicting an increasing toll on societal health and wellbeing. In this context, the latest SDG 3 GAP progress report pinpoints the interventions needed to realize the health-related Sustainable Development Goals and a revitalized global health ecosystem aligned with country priorities that safeguards the health of both people and planet – an attainable ambition that the United Nations Development Programme will continue to support with our partners across the globe.”
Dr Natalia Kanem, Executive Director, UNFPA:
“Thirty years since the adoption of the International Conference on Population and Development Programme of Action, the evidence is clear: resilient health systems are essential for ensuring universal access to sexual and reproductive health and rights – a cornerstone for achieving our 2030 targets. In a turbulent world, UNFPA and our partners in the SDG 3 Global Action Plan remain steadfast in our commitment to supporting country-led action to uphold the health, rights and choices of every woman and girl.”
Catherine Russell, UNICEF Executive Director:
“UNICEF is committed to realizing the Child Survival goals by 2030, with Primary Health Care as a critical investment to end preventable deaths and save the lives of women and children. These efforts must go hand-in-hand with interventions that protect girls, such as keeping them in school, while avoiding child marriages and early pregnancies. UNICEF supports the alignment of fully funded health plans under the leadership of national governments. Community Health Workers, who are trained and paid, and who have access to well-resourced primary health care facilities, are key to accelerating progress on child survival and development.”
Dr Philippe Duneton, Executive Director, Unitaid:
“A coordinated global health response is critical to achieving the Sustainable Development Goals. We rely on mechanisms like the Global Action Plan to monitor our progress and help us refine our approach so we can reach more people with vital care and improve global health for all.”
Sima Bahous, Executive Director, UN Women:
“Unlocking the full potential of the 2030 Agenda lies upon achieving gender equality and championing the rights of all women and girls everywhere. SDG3, aiming at achieving good heath and well-being for all, is no exception. UN Women encourages all stakeholders to double their actions, to dedicate resources at the grassroots level and to dismantle discriminatory norms. Together, we can pave the way for a future where every woman and girl thrives, where their health and well-being prospers without barriers.”
Dr Mamta Murthi, Vice President for Human Development, World Bank Group:
“Investing in people’s health and nutrition creates human capital and is a key driver for ending poverty on a livable planet. With governments around the world under increasing financial constraints, we need to make sure that health investments remain a priority. By working together in support of country-led plans to strengthen health systems, partners can help countries crowd-in resources and use them effectively to improve health outcomes and make progress towards the health-related SDGs.”
Cindy McCain, Executive Director, World Food Programme:
“Robust health and balanced nutrition are two sides of the same coin so it’s vital that we all work together to address the causes of hunger, malnutrition and illness. The SDG3 Global Action Plan provides a valuable route map to help us collaborate even more effectively, paving the way to a healthier, hunger-free future for all.”
SDG3 GAP agencies
- Gavi, the Vaccine Alliance
- Global Financing Facility for Women, Children and Adolescents (GFF)
- International Labour Organization (ILO)
- Joint United Nations Programme on HIV/AIDS (UNAIDS)
- The Global Fund to Fight AIDS, Tuberculosis and Malaria (The Global Fund)
- Unitaid
- United Nations Development Fund (UNDP)
- United Nations Population Fund (UNFPA)
- United Nations Children’s Fund (UNICEF)
- United Nations Entity for Gender Equality and the Empowerment of Women (UN Women)
- World Bank Group
- World Food Programme (WFP)
- World Health Organization (WHO)
Le Forum sur la mobilisation de l’industrie qui se tient à Lagos vise à accroître la fabrication de produits de santé en Afrique
Lagos (Nigéria) – Le Forum sur la mobilisation de l’industrie 2024 (Industry Engagement Forum) se tiendra du 7 au 9 mai 2024 à Lagos (Nigéria) sur le thème « Débloquer les chaînes de valeur des soins de santé et stimuler l’investissement grâce aux partenariats : accélérer l’accès équitable à des produits de santé durables de qualité garantie ». Plus de 300 participants sont attendus au forum, qui vise à accélérer l’accès équitable aux produits de santé nécessaires de toute urgence grâce à des partenariats collaboratifs et à faciliter les opportunités d’investissement en tant qu’interventions visant à accroître la fabrication locale de produits pharmaceutiques.
Le forum est organisé conjointement par la Banque africaine de développement (BAD), la Société financière internationale (IFC) et l’organisme de santé mondiale Unitaid, en association avec l’Initiative présidentielle pour débloquer les chaînes de valeur des soins de santé (PVAC) relevant du Ministère nigérian de la santé et de la protection sociale. L’initiative s’inscrit dans une démarche stratégique visant à débloquer des milliards en nouveaux investissements et à remodeler le paysage des soins de santé au Nigéria et en Afrique grâce à des partenariats multidimensionnels et à des engagements financiers substantiels.
Alors que 25 % de la charge mondiale de morbidité – y compris des principales maladies infectieuses que sont le VIH, la tuberculose et le paludisme – est concentrée en Afrique, plus de 95 % des principes actifs pharmaceutiques et 70 % des produits pharmaceutiques consommés sur le continent sont importés. Cela rend les pays vulnérables à la volatilité des prix, aux perturbations de la chaîne d’approvisionnement et à l’indisponibilité des produits de santé essentiels, en particulier pendant les périodes de pénurie d’approvisionnement du fait d’une hausse de la demande régionale ou mondiale, de chocs liés au climat ou de phénomènes météorologiques extrêmes.
L’adoption d’une approche ingénieuse de renforcement de la fabrication régionale afin de garantir la disponibilité des tests de dépistage, des traitements et des outils de santé sur le continent africain permettra d’améliorer la sécurité sanitaire, d’élargir l’accès durable à des solutions sanitaires accessibles financièrement et d’offrir des solutions adaptées aux besoins régionaux. Cela apportera en outre une contribution importante aux objectifs de développement durable (ODD) liés à la santé et appuiera la réalisation des cibles climatiques en réduisant les coûts de transport et les émissions de carbone.
« L’industrialisation du secteur de la santé n’est plus une option. C’est un impératif et une nécessité pour la stabilité et la croissance futures », a déclaré le Dr Abdu Mukhtar, coordonnateur national de la PVAC.
Le forum réunira des représentants internationaux et africains de l’industrie des soins de santé, notamment des organismes gouvernementaux, des instituts de recherche, des organismes de réglementation, des partenaires industriels, des partenaires de développement, des institutions de financement du développement, des organismes donateurs et des fondations s’attachant à garantir l’accès aux médicaments et aux produits de diagnostic. Trois jours durant, les participants discuteront de la création de chaînes de valeur régionales durables pour les produits de santé, essentielles à l’instauration de la couverture sanitaire universelle et au renforcement de la sécurité sanitaire sur l’ensemble du continent.
« La forte dépendance de l’Afrique à l’égard des produits pharmaceutiques et des vaccins importés (50 % à 70 % ou plus) préoccupe l’IFC. Les récentes perturbations de la chaîne d’approvisionnement durant la pandémie ont mis en évidence les risques que suppose une forte dépendance vis-à-vis des importations dans le secteur de la santé. La coorganisation de cet événement en Afrique témoigne de notre engagement à renforcer les chaînes de valeur de la fabrication locale et à créer des écosystèmes de santé résilients. La vigueur du secteur pharmaceutique nigérian et ses réformes réglementaires volontaristes en faveur de la couverture sanitaire universelle font de ce pays un choix révélateur pour cet événement », a déclaré Dahlia Khalifa, Directrice régionale d’IFC pour l’Afrique centrale, le Libéria, le Nigéria et la Sierra Leone.
Les points forts du forum comprendront des tables rondes sur les meilleures pratiques de fabrication de produits de santé de qualité garantie, sur les opportunités de financement stratégique et sur le rôle de la technologie numérique dans l’amélioration des réseaux de distribution des produits de santé. Des cliniques d’investissement et des opportunités de réseautage seront également organisées afin de stimuler les collaborations entre entreprises et entre pouvoirs publics et entreprises.
« La Banque africaine de développement met en œuvre un plan d’action pharmaceutique novateur doté de 100 millions de dollars d’investissements par an, destiné à renforcer l’écosystème pharmaceutique africain grâce à des interventions et à des partenariats stratégiques mobilisant le secteur public et le secteur privé », a affirmé Solomon Quaynor, Vice-Président du complexe Secteur privé, infrastructure et industrialisation. « À l’occasion du Forum sur la mobilisation de l’industrie des soins de santé, nous présenterons notre plan d’action pharmaceutique 2021-2030 visionnaire ainsi qu’un large éventail d’outils financiers et autres conçus pour autonomiser le secteur pharmaceutique privé. »
Le continent africain abrite près de 17 % de la population mondiale, soit presque 1,3 milliard de personnes, or il ne fabrique que 3 % des médicaments produits à l’échelle mondiale. Il est essentiel de réduire considérablement la dépendance à l’égard des produits de santé importés en Afrique pour garantir le succès et la durabilité des programmes de santé publique sur l’ensemble du continent, si nous voulons parvenir à la couverture sanitaire universelle et réaliser l’ODD 3 relatif à la bonne santé et au bien-être en renforçant les systèmes de santé et l’équité sociale et en améliorant le bien-être général.
« Le moment est venu d’investir dans la fabrication, en Afrique, de produits de santé de qualité garantie et accessibles financièrement. Le panorama actuel de la santé mondiale, conjugué aux capacités croissantes de l’Afrique en matière de fabrication de produits pharmaceutiques, offre une occasion unique de mettre en place des systèmes de santé plus solides et autosuffisants dans l’ensemble du continent », a déclaré Robert Matiru, Directeur des programmes d’Unitaid. « En localisant la production, nous améliorons l’accès aux produits de santé essentiels, réduisons la dépendance à l’égard des chaînes d’approvisionnement internationales et autonomisons les économies locales. Le renforcement de la production régionale est essentiel à la durabilité et à la résilience des services de santé. Il est crucial que les parties prenantes s’attachent ensemble à mettre en œuvre cette vision. »
Le Forum sur la mobilisation de l’industrie 2024 s’inscrit dans le cadre d’une série d’événements de mobilisation des parties prenantes organisés dans le monde entier pour promouvoir l’accès à l’innovation en santé, soutenir l’accès équitable aux solutions de soins de santé et renforcer les capacités aux fins de l’efficacité de la préparation et de la riposte face aux urgences sanitaires dans les pays à revenu faible ou intermédiaire. L’événement sera retransmis en direct. Inscrivez-vous ici pour y participer en ligne.
Contacts :
Banque africaine de développement :
Questions techniques : Dre Ghada Abuzaid, g.abuzaid@afdb.org, +2250575750903
Médias : Communication et relations extérieures, media@afdb.org
IFC : Hawa S Diop, diop1@ifc.org, +1 202 696 47 16
PVAC : Enitan Tejuoso, eniitantej@gmail.com, +2349062021212, WhatsApp +18602801640
Unitaid : Melanie Brooks, brooksm@who.int, +41 79 525 62 91
À propos du Groupe de la Banque africaine de développement (BAD)
Le Groupe de la Banque africaine de développement est la principale institution de financement du développement d’Afrique. Il comprend trois entités distinctes : la Banque africaine de développement (BAD), le Fonds africain de développement (FAD) et le Fonds spécial du Nigéria (FSN). Présente dans 41 pays africains ainsi qu’au Japon par l’intermédiaire d’un bureau de représentation extérieure, la Banque contribue au développement économique et au progrès social de ses 54 États Membres régionaux. Pour plus d’informations, veuillez consulter le site Web de la BAD à l’adresse www.afdb.org.
À propos de la Société financière internationale (IFC)
Membre du Groupe de la Banque mondiale, la Société financière internationale (IFC) est la plus grande institution mondiale de développement axée sur le secteur privé dans les marchés émergents. Actifs dans plus de 100 pays, nous mettons nos ressources financières, nos compétences et notre influence au service de la création de marchés et d’opportunités dans les pays en développement. Au cours de l’exercice 2023, l’IFC a engagé un montant record de 43,7 milliards de dollars en faveur de sociétés privées et d’institutions financières des pays en développement, tirant parti de la puissance du secteur privé pour mettre fin à l’extrême pauvreté et stimuler une prospérité partagée tandis que les économies sont aux prises avec les répercussions des crises mondiales conjuguées. Pour plus d’informations, veuillez consulter le site Web de l’IFC à l’adresse www.ifc.org.
À propos de l’Initiative présidentielle pour débloquer la chaîne de valeur des soins de santé (PVAC)
L’Initiative présidentielle pour débloquer la chaîne de valeur des soins de santé (PVAC) est une initiative gouvernementale qui vise à servir de catalyseur de la sécurité sanitaire nationale et régionale ainsi que de la croissance économique et de l’emploi, en accélérant la transformation de la chaîne de valeur des soins de santé au Nigéria grâce à la coordination et à la collaboration entre les différentes institutions.
À propos d’Unitaid
Unitaid est un organisme de santé mondiale qui sauve des vies en s’assurant que les nouveaux produits de santé disponibles et financièrement abordables dans les pays à revenu faible ou intermédiaire. Unitaid collabore avec ses partenaires en vue d’identifier des traitements, des tests de dépistage et des outils novateurs, de contribuer à lever les obstacles qui entravent leur distribution afin que ceux qui en ont le plus besoin puissent y accéder dans les meilleurs délais. Depuis sa création en 2006, Unitaid a participé au déploiement de plus de 100 produits de santé révolutionnaires pour aider à relever les plus grands défis auxquels le monde est confronté en matière de santé, notamment le VIH, la tuberculose et le paludisme ; la santé des femmes et des enfants ; et la prévention, la préparation et la riposte face aux pandémies. Chaque année, plus de 300 millions de personnes bénéficient des produits dont Unitaid a contribué à garantir la disponibilité. Unitaid est hébergé par l’Organisation mondiale de la Santé.
Comment Unitaid apporte un soutien au programme de santé du G20 du Brésil grâce à des solutions novatrices
The Group of Twenty (G20) convenes the world’s major economies to influence international policies on key issues such as trade, health, climate, and more. Led by Brazil this year, and within the G20 framework, specialized Working Groups made up of experts and officials from relevant ministries facilitate discussions on these topics as part of the collective decision-making process. The G20 health working group focuses on pressing global health issues and fosters international collaboration and collective action. Unitaid actively participates in the G20 Health Working Group, contributing expertise and resources to help shape effective health strategies and policies.
Discussions at this year’s G20 health working group meetings are focused on innovative approaches to today’s global health challenges while charting a path toward more resilient health systems. Under its G20 presidency, Brazil is steering the health agenda toward expansive and inclusive policies with an emphasis on four key priorities:
- Pandemic prevention, preparedness and response with a focus on local and regional production of medicines, vaccines and strategic health supplies
- The expansion of digital health technologies
- Equitable access to health innovations
- The integration of climate considerations into health policies
These four priority areas for the G20 come at a crucial moment, as the global health infrastructure buckles under post-pandemic realities on top of emerging threats like climate change and antimicrobial and insecticide resistance. Unitaid’s core work—with support from many G20 countries and observers—aligns well with Brazil’s key priority areas in addressing today’s challenges. By accelerating access to innovative health products in low- and middle-income countries, Unitaid is helping to create a more resilient global health system and stands ready to work with G20 members and the broader international community to advance these vital health priorities.
Concrete results expected of the G20 health working group this year include establishing a multilateral alliance for access, innovation and regional production. Unitaid welcomes the initiative of the Brazilian presidency to emphasize health equity in this proposal, recognizing that access is not an afterthought and that the needs of patients must be addressed from the research and development phase to product delivery. Equitable access to health innovation is the cornerstone of the Unitaid strategy and is a founding principle. Without specific intervention to ensure access, medical innovations typically take 10 years to reach the most vulnerable people. By the time key health products and medicines arrive in low- and middle-income countries, they lack market incentives and are maladapted to the needs of the population.
Equitable access to a lifesaving product requires that the product is developed in the first place, and collaborative research and development with a targeted agenda can address gaps in the public health response against key diseases where the market fails. As Brazil’s G20 presidency prioritizes local and regional production in pandemic prevention, preparedness, and response, Unitaid reiterates its dedication to supporting an equitable innovation agenda that can fast-track the development of new treatments and diagnostic tools that are fit to serve the populations in need. Likewise, dedicated efforts are ongoing at Unitaid to accelerate access to transformative new technologies, such as long-acting injectables and monoclonal antibodies, which may enable access to much-needed products today while equipping us for new threats in the future, including pandemics or climate-induced health crises.
Unitaid’s strategy extends to boosting regional production capabilities to ensure these vital resources are available to respond to major persistent health issues and crises, especially in low—and middle-income countries. We have seen that sustainable and competitive production of key quality-assured and price-competitive products at the regional level is viable. For example, with Unitaid support, the first African manufacturer attained the required WHO prequalification status to become a global supplier of lifesaving antimalarial medication. Thanks to a technology transfer from the UK and the Republc of Korea – facilitated by Unitaid and partners – regional production for COVID-19 rapid tests began in Senegal during the pandemic, and shifted to produce tests for other diseases beyond the crisis phase. There is now an opportunity to embrace dual-purpose investments that have a viable demand during inter-crisis periods and can pivot to producing pandemic products during health emergencies.
Regional manufacturing has been one of the tools in Unitaid’s market-shaping toolbox for access. To succeed, the following four elements must be met:
- First is the financial viability of regional production, which hinges on market prospects and sufficiently funded demand. Sustained efforts and collaboration are needed to foster demand aggregation and build regional markets large enough to benefit from economies of scale. G20 countries’ purchasing power is a key element to render such efforts viable, as very few countries are large enough to do this independently.
- Second, attaining global quality-assurance standards will enable regional manufacturers to rise as global and regional suppliers. There is a limited pool of manufacturers with sufficient production capacity and experience to meet the requisite quality assurance standards requested by domestic regulations and large purchase funds, undermining market viability.
- Third, creating more efficient regulatory processes across regional and global levels, particularly for new technologies. The complexity of overlapping and often conflicting regulatory processes across multiple mechanisms at the regional and global levels is a barrier.
- Fourth, building strategic plans built on robust analyses to ensure end-to-end viability of value chains, from the synthesis of active pharmaceutical ingredients and other critical inputs, to the final formulation of finished pharmaceutical products(or diagnostic tests).
Regional manufacturing can also enable regions to customize and adapt health products to local contexts where global innovation is not adapted or insufficient; it can enhance local expertise, support knowledge transfer and capacity building, bridge the gap between innovation and manufacturing capacity, and strengthen regional regulation.
Embracing regional manufacturing also has the potential to support another priority under Brazil’s G20 presidency: the adoption of climate-resilient value chains. As an organization focused on access to optimized health products for LMICs, Unitaid already works with a wide range of partners who develop, manufacture, procure, and promote the use of key health products, and has a strategy in place to advance “climate-smart” healthcare solutions that are more resilient to climate change and involve green manufacturing and distribution models.
Supporting equitable access and boosting innovation targeting patients’ needs is also key when addressing antimicrobial resistance. Resistance to critical medicines and insecticides threatens to stall – or reverse – progress in the fight against infectious disease. Unitaid welcomes the reinforced efforts under this presidency to advance the pipeline of tools to improve the AMR fight, given the widening gaps in innovation, market entry, country adoption, and adequate use of new regimens for antimicrobial resistance. Through a diverse portfolio, Unitaid addresses current market failures by supporting access to adapted therapeutics and diagnostics to prevent, monitor, and contain resistance. This includes better formulations and new-drug delivery technologies that can help promote adherence and protect existing therapeutics for infectious diseases.
Finally, and in line with Brazil’s emphasis on digital health, Unitaid actively supports optimizing the integration of digital technologies in healthcare. Our projects leverage digital technology like smart pillboxes, video-supported treatments, and medication labels to support adherence and referral to care in tuberculosis, using artificial intelligence for diagnostics in tuberculosis or cervical cancer, and digital innovations in maternal and child health. These efforts are essential in enhancing data integration within national health systems and expanding telehealth services in low- and middle-income countries.
Unitaid’s alignment with Brazil’s G20 health priorities underscores our shared commitment to enhancing global health security and equity. Our efforts to support equitable innovation, facilitate regional production capabilities, integrate climate-resilient solutions, expand digital health innovations, and prevent antimicrobial resistance are well-positioned to help G20 countries build a more robust global health system. As we continue to support these initiatives, Unitaid remains dedicated to advancing collaborative solutions that respond to today’s urgent health needs while preparing for tomorrow’s challenges.
Media Contact
Kyle Wilkinson, Media Officer, Unitaid
wilkinsonk@unitaid.who.int
+41 79 445 1745
